|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009429,
umls-concept:C0025543,
umls-concept:C0030705,
umls-concept:C0205390,
umls-concept:C0279628,
umls-concept:C0331858,
umls-concept:C0445204,
umls-concept:C0919273,
umls-concept:C1704640,
umls-concept:C1706515,
umls-concept:C1999216,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-5-9
|
|
pubmed:abstractText |
This randomized phase II, parallel-design study evaluated preoperative combined modality therapy and the matrix metalloprotease (MMP) inhibitor prinomastat in patients with resectable adenocarcinoma of the esophagus that were stage II or greater. The objectives of the trial were to determine pathologic complete response rate (pCR), overall response rate, progression-free survival, pattern of disease relapse, and two-year and overall survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0167-6997
|
|
pubmed:author |
pubmed-author:BurtnessBarbara ABA,
pubmed-author:CantoMarcia IMI,
pubmed-author:CollierMaryM,
pubmed-author:ForastiereArlene AAA,
pubmed-author:HeathElisabeth IEI,
pubmed-author:HeitmillerRichard FRF,
pubmed-author:KleinbergLawrenceL,
pubmed-author:KniselyJonathan P SJP,
pubmed-author:MontgomeryElizabethE,
pubmed-author:PithavalaYazdiY,
pubmed-author:RohmillerBridgetB,
pubmed-author:SalemRonald RRR,
pubmed-author:TopazianMarkM,
pubmed-author:TsottlesNancyN,
pubmed-author:YangStephen CSC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
135-40
|
|
pubmed:meshHeading |
pubmed-meshheading:16502351-Adenocarcinoma,
pubmed-meshheading:16502351-Combined Modality Therapy,
pubmed-meshheading:16502351-Esophageal Neoplasms,
pubmed-meshheading:16502351-Esophagectomy,
pubmed-meshheading:16502351-Humans,
pubmed-meshheading:16502351-Male,
pubmed-meshheading:16502351-Matrix Metalloproteinases,
pubmed-meshheading:16502351-Middle Aged,
pubmed-meshheading:16502351-Neoadjuvant Therapy,
pubmed-meshheading:16502351-Neoplasm Staging,
pubmed-meshheading:16502351-Organic Chemicals,
pubmed-meshheading:16502351-Protease Inhibitors,
pubmed-meshheading:16502351-Thromboembolism
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
|
|
pubmed:affiliation |
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. heathe@karmanos.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Clinical Trial, Phase II
|
